LEXINGTON, Mass. — Aldeyra Therapeutics, Inc. (Nasdaq: ALDX), a biotechnology company focused on developing therapies for immune-mediated diseases, announced during a research and development webcast that it is expanding its Reactive Aldehyde Species (RASP) platform to include programs targeting central nervous system diseases associated with inflammation. The company also provided updates regarding manufacturing inspections for reproxalap.
According to Aldeyra, new preclinical findings in models of Parkinson’s disease and amyotrophic lateral sclerosis demonstrated improvements in grip strength, balance, and biomarkers of central nervous system function. Based on these results, potential clinical indications for ADX-248, the company’s orally administered, next-generation RASP modulator, have broadened to include neuroinflammatory diseases affecting the central nervous system.
The company also reported that the U.S. Food and Drug Administration completed routine inspections of reproxalap drug substance and drug product manufacturing facilities in 2025. The inspections resulted in Voluntary Action Indicated designations, and the FDA notified the manufacturers that the inspections are closed with no further action required.
“A testament to the growing opportunity for immune-modulating therapeutic approaches, the new results announced today in preclinical models of neurological diseases associated with inflammation highlight the potentially broad applicability of ADX-248 and other next-generation RASP modulators as novel product candidates for the treatment of a number of clinical indications,” said Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra. “We look forward to providing future updates on ADX-248, reproxalap, and other RASP modulators as we advance our therapeutic pipeline.”
